[Skip to Content]
[Skip to Content Landing]
Article
September 1983

Argon Laser Photocoagulation for Ocular HistoplasmosisResults of a Randomized Clinical Trial

Arch Ophthalmol. 1983;101(9):1347-1357. doi:10.1001/archopht.1983.01040020349002
Abstract

• The Ocular Histoplasmosis Study (OHS) is a multicenter controlled clinical trial designed to determine whether argon laser photocoagulation is useful in preventing severe visual acuity loss in eyes with choroidal neovascular membranes (NVMs) 200 to 2,500 μm from the center of the foveal avascular zone and evidence of ocular histoplasmosis. Eligible patients were assigned to photocoagulation (n = 124) or to observation only (n = 121) groups. Recruitment of patients who have extrafoveal NVMs for the OHS has been terminated because more untreated eyes than treated eyes had experienced severe visual acuity loss. At the most recent follow-up visit (median follow-up, 18 months), 34.2% (39/114) of untreated eyes v 9.4% (11/117) of treated eyes had lost six or more lines of visual acuity from the baseline level. The superiority of argon laser photocoagulation was evident in all subgroups and at every point in follow-up time, indicating that patients who meet the eligibility criteria will benefit from treatment. Follow-up of all patients continues in order to assess long-term results of treatment.

References
1.
 Argon laser photocoagulation for senile macular degeneration: Results of a randomized clinical trial . Macular Photocoagulation Study Group. Arch Ophthalmol 1982;100:912-918.Article
2.
Gass JDM:  Choroidal neovascular membranes: Their visualization and treatment . Trans Am Acad Ophthalmol Otolaryngol 1973;77:310-320.
3.
Schlaegel TF, Cofield DD, Clark G, et al:  Photocoagulation and other therapy for histoplasmic choroiditis . Trans Am Acad Ophthalmol Otolaryngol 1968;72:355-363.
4.
Gutman FA:  The natural course of active choroidal lesions in the presumed ocular histoplasmosis syndrome . Trans Am Ophthalmol Soc 1979;77:515-541.
5.
Watzke RC, Leaverton PA:  Light photocoagulation in presumed histoplasmic choroiditis: A controlled clinical study . Arch Ophthalmol 1971; 86:127-132.Article
6.
Gass JDM, Wilkinson CP:  Follow-up study of presumed ocular histoplasmosis . Trans Am Acad Ophthalmol Otolaryngol 1972;76:672-693.
7.
Okun E:  Photocoagulation treatment of presumed ocular histoplasmic choroidopathy . Trans Am Ophthalmol Soc 1972;70:467-489.
8.
Klein ML, Fine SL, Knox DL, et al:  Followup study in eyes with choroidal neovascularization caused by presumed ocular histoplasmosis . Am J Ophthalmol 1977;83:830-835.
9.
Klein ML, Fine SL, Patz A:  Results of argon laser photocoagulation in presumed ocular histoplasmosis . Am J Ophthalmol 1978;86:211-217.
10.
Lewis ML, Van Newkirk MR, Gass JDM:  Follow-up study of presumed ocular histoplasmosis syndrome . Ophthalmology 1980;87:390-399.Article
11.
Cantrill HL, Burgess D:  Peripapillary neovascular membranes in presumed ocular histoplasmosis . Am J Ophthalmol 1980;89:192-203.
12.
Watzke RC, Claussen RW:  The long-term course of multifocal choroiditis (presumed ocular histoplasmosis) . Am J Ophthalmol 1981;91:750-760.
13.
Olk RJ, Fine SL, Scheraga D, et al:  Longterm follow-up of ocular histoplasmosis treated by argon laser photocoagulation . Retina 1981; 1:238-244.Article
14.
Sabates FN, Lee KY, Ziemianski MC:  A comparative study of argon and krypton laser photocoagulation in the treatment of presumed ocular histoplasmosis syndrome . Ophthalmology 1982;89:729-734.Article
15.
Bailey IL, Lovie JE:  New design principles for visual acuity letter charts . Am J Optom Physiol Optic 1976;53:740-745.Article
16.
Armitage P: Statistical Methods in Medical Research . New York, John Wiley & Sons Inc, 1971.
17.
Kaplan EL, Meier P:  Nonparametric estimation from incomplete observations . J Am Stat Assoc 1958;53:457-481.Article
18.
Mantel N:  Evaluation of survival data and two new rank order statistics arising in its consideration . Cancer Chemother Rep 1966; 50:163-170.
19.
Peto R, Peto J:  Asymptotically efficient rank invariant test procedures . J R Stat Soc A 1972;135( (pt 2) ):185-206.Article
20.
Cox DR:  Regression models and life-tables . J R Stat Soc B 1972;2:187-220.
21.
Yassur Y, Gilad E, Ben-Sira I:  Treatment of macular subretinal neovascularization with the red-light kyrpton laser in presumed ocular histoplasmosis syndrome . Am J Ophthalmol 1981;91:172-176.
22.
Bird AC, Grey RHB:  Photocoagulation of disciform macular lesions with krypton laser . Br J Ophthalmol 1979;63:669-673.Article
23.
Sabates F, Lee K, Ziemianski M, et al: Update in the management of SRNV. Presented at the annual meeting of the Macula Society, Orlando, Fla, March 3, 1983.
24.
Sawelson H, Goldberg RE, Annesley WH, et al:  Presumed ocular histoplasmosis syndrome: The fellow eye . Arch Ophthalmol 1976;94:221-224.Article
25.
Manual of Operations. Macular Photocoagulation Study Group. Springfield, Va, National Technical Information Service, accession No. PB82-221482.
26.
Senile Macular Degeneration Data Forms. Macular Photocoagulation Study Group. Springfield, Va, National Technical Information Service, accession No. PB82-217043.
27.
Ocular Histoplasmosis and Idiopathic Neovascularization Data Forms. Macular Photocoagulation Study Group. Springfield, Va, National Technical Information Service, accession No. PB83-232686.
28.
Data and Safety Monitoring Committee Report: Senile Macular Degeneration. Macular Photocoagulation Study Group. Springfield, Va, National Technical Information Service, accession No. PB83-168179.
29.
Data and Safety Monitoring Committee Report: Ocular Histoplasmosis and Idiopathic Neovascularization. Macular Photocoagulation Study Group. Springfield, Va, National Technical Information Service, accession No. PB83-232678.
30.
Bailey NTJ: The Elements of Stochastic Processes . New York, Wiley & Sons Inc, 1964.
31.
Edwards LB, Acquaviva FA, Livesay VT, et al:  An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States . Am Rev Respir Dis 1969;99( (pt 2) ):1-132.
×